These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 17895486)

  • 21. The story of drotrecogin alfa - evidence-based or evidence-biased?
    Wiseman R; Blockman M
    S Afr Med J; 2011 Dec; 102(1):8. PubMed ID: 22273122
    [No Abstract]   [Full Text] [Related]  

  • 22. [Can we still afford progress in intensive care medicine? Re: the article from DMW 1-2/2004].
    Kalenka A
    Dtsch Med Wochenschr; 2004 Jul; 129(31-32):1698-9; author reply 1699-70. PubMed ID: 15273924
    [No Abstract]   [Full Text] [Related]  

  • 23. Drotrecogin alfa: new preparation. For some cases of severe sepsis?
    Prescrire Int; 2003 Apr; 12(64):55-7. PubMed ID: 12674116
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Economic evaluation of new therapies in critical illness.
    Coughlin MT; Angus DC
    Crit Care Med; 2003 Jan; 31(1 Suppl):S7-16. PubMed ID: 12544971
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacoeconomic concepts in antiplatelet therapy: understanding cost-effectiveness analyses using clopidogrel as an example.
    Weintraub WS
    J Cardiovasc Pharmacol Ther; 2008 Jun; 13(2):107-19. PubMed ID: 18495905
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacoeconomic implications of new therapies in sepsis.
    Wood KA; Angus DC
    Pharmacoeconomics; 2004; 22(14):895-906. PubMed ID: 15362927
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Severe sepsis and the role of novel therapeutic agents. Position statement of the Critical Care Society of South Africa on severe sepsis and the role of novel therapeutic agents such as drotrecogin alfa (activated).
    Critical Care Society of South Africa Working Group
    S Afr Med J; 2003 Jun; 93(6):416-7. PubMed ID: 12916374
    [No Abstract]   [Full Text] [Related]  

  • 28. Severe sepsis management are we doing enough?
    Ahrens T; Vollman K
    Crit Care Nurse; 2003 Oct; 23(5 Suppl):2-15; quiz 17. PubMed ID: 14619742
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Timing of drotrecogin alfa (activated) initiation in treatment of severe sepsis: a database cohort study of hospital mortality, length of stay, and costs.
    Ernst FR; Johnston JA; Pulgar S; He J; Ball DE; Young JK; Cooper LM
    Curr Med Res Opin; 2007 Jan; 23(1):235-44. PubMed ID: 17207305
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Cost-effectiveness of new drugs impacts reimbursement decision making but room for improvement].
    Hoomans T; van der Roer N; Severens JL; Delwel GO
    Ned Tijdschr Geneeskd; 2010; 154():A958. PubMed ID: 20699045
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drotrecogin alfa: a second look. More clinical trials in severe sepsis: mostly negative results.
    Prescrire Int; 2007 Feb; 16(87):7-9. PubMed ID: 17323514
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Expensive modern therapy options in intensive care medicine in Germany-- are they being used? Results of a questionnaire].
    Boldt J; Papsdorf M
    Dtsch Med Wochenschr; 2005 Jan; 130(3):87-91. PubMed ID: 15650957
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Advances in treating patients with severe sepsis. Role of drotrecogin alfa (activated).
    Kleinpell R
    Crit Care Nurse; 2003 Jun; 23(3):16-29; quiz 67-8. PubMed ID: 12830777
    [No Abstract]   [Full Text] [Related]  

  • 34. International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: analysis of efficacy and safety data in a large surgical cohort.
    Payen D; Sablotzki A; Barie PS; Ramsay G; Lowry S; Williams M; Sarwat S; Northrup J; Toland P; McL Booth FV
    Surgery; 2006 Nov; 140(5):726-39. PubMed ID: 17084715
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Activated protein C for severe sepsis.
    Garces K
    Issues Emerg Health Technol; 2002 Mar; (30):1-4. PubMed ID: 11985365
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Medicare to partly cover extra cost of sepsis therapy, drug-eluting stents.
    Thompson CA
    Am J Health Syst Pharm; 2002 Oct; 59(19):1816-7. PubMed ID: 12374063
    [No Abstract]   [Full Text] [Related]  

  • 37. The use of drotrecogin alfa (activated) in severe sepsis during acute pancreatitis - two case studies.
    Machała W; Wachowicz N; Komorowska A; Gaszyński W
    Med Sci Monit; 2004 Jul; 10(7):CS31-6. PubMed ID: 15232511
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drotrecogin alfa (recombinant human activated protein C) in severe acute pancreatitis.
    Jamdar S; Siriwardena AK
    Crit Care; 2005 Aug; 9(4):321-2. PubMed ID: 16137370
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Activated protein C, coagulation, inflammation and treatment of severe sepsis].
    Ott A
    Ned Tijdschr Geneeskd; 2001 Nov; 145(45):2196-7. PubMed ID: 11727624
    [No Abstract]   [Full Text] [Related]  

  • 40. Role of activated protein C in the pathophysiology of severe sepsis.
    Dettenmeier P; Swindell B; Stroud M; Arkins N; Howard A
    Am J Crit Care; 2003 Nov; 12(6):518-24; quiz 525-6. PubMed ID: 14619357
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.